InvestorsHub Logo
Followers 3
Posts 302
Boards Moderated 0
Alias Born 05/05/2004

Re: None

Thursday, 10/05/2017 10:36:29 AM

Thursday, October 05, 2017 10:36:29 AM

Post# of 1706
Okay, so if you're new to EDAP, here's what's going on. They are based in France and develop medical products. Their specialty is HIFU, or High Intensity Focused Ultrasound. Focused ultrasound waves can heat up and destroy tumors. It is a proven technology and way less invasive than surgery and way less traumatic than chemotherapy.

Until yesterday, their products have been approved all over Europe and Asia, but not in America. They have tried and failed to get approval for these products several times. This time they succeeded with one.

The two products with most potential IMO are Ablatherm and Focal One. Ablatherm is a manually operated device that treats prostate cancer with HIFU and Focal One is a robotic equivalent. Ablatherm was approved by the FDA yesterday and Focal One has been submitted for approval but no decision is expected until some time next year.

Management owns very few shares of stock and has been slow over the years to get their technology approved in the US. A lot of this has been due to missteps in filing the paperwork and test data to the FDA. No idea why management owns so few shares of stock. The lack of insider ownership has always been a concern to common shareholders.

Institutional ownership, on the other hand, is healthy and has been growing lately.

Short interest has been going up and down lately, hovering around three percent. I don't expect a very big short squeeze, if any. Shorts will quietly cover and move on.






Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EDAP News